Psychometric validation of the EORTC QLQ-HCC18 in patients with previously treated unresectable hepatocellular carcinoma.
| Publicado en: | Quality of Life Research Vol. 31; no. 3; pp. 937 - 951 |
|---|---|
| Autores principales: | , , , , |
| Formato: | research tables/charts Journal Article |
| Publicado: |
Springer Nature
Mar2022
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=155758486&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 155758486 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 09629343 GPQ jtl: Quality of Life Research issn: 09629343 maglogo: N pubinfo: dt: Mar2022 vid: 31 iid: 3 pid: 237 pub: Springer Nature place: New York, New York artinfo: ui: 155758486 152434258 155758486 155758486 10.1007/s11136-021-02992-1 155758486 ppf: 937 ppct: 14 formats: fmt: – @attributes: type: T – @attributes: type: P tig: atl: Psychometric validation of the EORTC QLQ-HCC18 in patients with previously treated unresectable hepatocellular carcinoma. aug: au: Serrano, Daniel Podger, Lauren Barnes, Gisoo Song, James Tang, Boxiong affil: Pharmerit (An Open Health Company), 4350 East-West Highway, Suite 1100, 20814, Bethesda, MD, USA sug: subj: Instrument Validation Psychometrics Questionnaires Quality of Life Evaluation Carcinoma, Hepatocellular Drug Therapy Human Adult Cancer Patients Validation Studies Antibodies, Monoclonal Therapeutic Use Antibodies, Monoclonal Adverse Effects Internal Consistency Test-Retest Reliability Construct Validity Criterion-Related Validity Discriminant Validity Known Groups Fatigue Body Image Nutrition Cancer Pain Attitude to Sexuality Patient-Reported Outcomes Data Analysis Software Descriptive Statistics Adult: 19-44 years pubtype: Academic Journal doctype: research tables/charts Journal Article ougenre: Article ab: language: English refInfo: holdings: @attributes: islocal: N |
|---|